ArticlePakistan journal of medical sciences2025
High ceftazidime-avibactam resistance rate in carbapenem-resistant gram-negative organisms in Pakistan's pediatric population.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study investigates resistance to a newly available drug Ceftazidime-Avibactam (CAZ-AVI) in carbapenem-resistant gram-negative organisms (GNOs) in the Pakistan's pediatric population. Methods: This was a prospective study carried out in the Department of Microbiology at The Children's Hospital, Lahore from May 2023 to July 2023. A sum of 7491 specimens of blood, cerebrospinal fluid (CSF), urine, pus, nasal swabs, central venous catheter (CVP) tips and tracheal secretion were analyzed for presence of carbapenem resistant gram-negative organisms which were then further screened for CAZ-AVI resistance. Analytical profile index and Kirby-Bauer disk diffusion methods were used for the identification of organisms. Results: A total of 217(n) carbapenem-resistant bacterial species, including 165(n) Conclusion: Taking into account the results of this study, which depicted high resistance rates to CAZ-AVI among carbapenem resistant GNOs, and the high cost of this drug, it is suggested that a cautious selection for its use as monotherapy in sepsis and other infections should be made. It should be made mandatory to check the resistance to CAZ-AVI before its empiric use. The findings of the study also emphasize the challenges of combating new drug resistance and further research to adapt treatment strategies to the evolving antimicrobial resistance in the region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.